Peripartum cardiomyopathy is a specific cardiomyopathy in which heart failure develops during pregnancy or in the postpartum period in women without a history of cardiomyopathy, and reduced myocardial contraction is found on examination. Advanced age, hypertensive disorders in pregnancy (HDP) and multiple conception are well-known risk factors. Since symptoms of heart failure, including shortness of breath and excessive edema, are also frequent in healthy pregnant and parturient women, diagnosis is likely to be delayed. However, it should be included in differential diagnosis for pregnant and postpartum women who complain of those symptoms, especially with risk factors, because it may lead to maternal death in severe cases.
Basic studies in animal models have recently been reported, and an association between vascular disorders, such as HDP, and peripartum cardiomyopathy is currently attracting attention. Genetic analyses also revealed the overlap between peripartum cardiomyopathy and familial dilated cardiomyopathy.
Special caution is needed in heart failure therapy for pregnant women. Anti-prolactin therapy has been proposed as a novel treatment, based on the theory that cleaved prolactin is a cause of the disease.
View full abstract